SOT for Cancer, Lyme, Co-Infections and Viruses

---

Short Oligonucleotide Technique (SOT) is a treatment for specific infections (certain viruses and Lyme) and cancers. By silencing the genetic code of the infectious agents or cancer cells it is able to kill them. 

This breakthrough therapy utilizes molecular building blocks (mRNA) that are found naturally in the patient’s own body, it is not technically a drug since there is no gene manipulation therapy. SOT started at RGCC labs almost 10 years ago. At that time, it was and is still known as Antisense Oligodeoxynucleotide Therapy (AOT). It is under the later name (both names are the same in reality) that you will be able to find more information on the internet. It is backed by many years of research by European and American based companies and universities.

Nucleotides are the molecules that form the structure of DNA and RNA. “Oligo” means “few”. Thus, oligonucleotides consist of a short sequence of nucleotides rarely no longer 20 amino acids long. The term “antisense” oligodeoxynucleotide refers to the fact that it is designed to bind to its counterpart (mirror image) in the body, thus blocking its function.

RGCC, a medical genetics company in Greece has done of lot of work to enhance AOT. Their antisense molecule is now known as SOT and the treatment is uniquely tailored to each patient’s needs. It is a small oligodeoxynucleotide which is complementary to a specific sequence of each individual genes which is related to anti-apoptotic signals inside cancer cells. Apoptosis is another word for programmed cell death. In other words, the SOT molecule has a potent ability to block specific mRNA and block at a very high rate the expression and transcription of a gene which encodes a protein with anti-apoptotic effect. This explains why, with a single dose of SOT, we can turn off the replication cycles of 23 species of Lyme disease and some Lyme disease co-infections (specific viral infections), and cancer cells. The SOT molecules degrade very slowly and can therefore attack the mRNA in cancer, Lyme, and/or   viral cells for  many  months.

RGCC has state-of-the-art equipment and technology which enables them to identify specific gene sequences of various infectious agents and cancer cells. The patient’s blood is drawn at our clinic to obtain the pathogens and circulating cancer stem cells (CSCs). RGCC is able to identify the main gene epitope (gene sequence) of the target genes and to create the SOT. RGCC’s unique verification process includes cross referencing the main gene sequences with the information stored in an international genetics database. This makes it possible to have the most accurate SOT and to maximize the success of treatment. SOT  does  not  at  all  interfere

with the functioning of normal human cells, tissues, or organs. The term sense strand refers to the replication genes, the genes that cause cell replication. Once these genes are identified, RGCC creates an anti-copy or antisense strand of the replication sequences of the translocation genes. This anti-copy is a complementary copy of the DNA sequences that codes for replication. RGCC Labs uses miRNA (micro RNAs) to only influence certain gene expressions and not to change genetic structure. This is NOT a genetic therapy.

Subsequently, this anti-copy is surrounded  with a synthetic messenger RNA (mRNA) to enable it to penetrate the target’s cell wall. Next, this mRNA is replicated to ~500 million to 1 billion copies of SOT molecules which are personalized  for  each individual. Finally, RGCC ships the SOT to the doctor’s office where  it  will be administered to the patient. After the intravenous infusion, the SOT molecules w ill work around the clock for about six months, during which time they will inhibit the replication of the target infectious agents or cancer cells.

Follow-up testing is strongly recommended to see when the virus/Lyme infection is resolved and in cancer to confirm the amount of CSC is decreasing.

Currently, the SOT is available for the following Lyme species and co-infections: 

Borrelia mayonii

Borrelia burgdorferi

Borrelia garinii

Borrelia bissettii

Borrelia bavariensis

Borrelia miyamotoi

Candidatus Borrelia tachyglossi

Borrelia valaisiana

Borrelia afzelii

Borrelia finlandensis
Borrelia recurrentis

Bartonella henselae

Bartonella bacilliformis

Bartonella vinsonii

Bartonella quintana

Babesia microti

Babesia bigemina

Babesia divergens

Babesia duncani

Babesia bovis

Borrelia valaisiana

Borrelia hermsii

Borrelia lusitaniae

Borrelia sinica

Candidatus Borrelia

Borrelia miyamotoi

elizabethae

and for the following viruses:

EBV (Epstein Barr Virus)
CMV (cytomegalovirus)

Coxsackie virus (Types A & B)

VZV (Varicella Zoster virus (chicken pox, shingles))

HHV1/HSV1 (oral herpes virus)

HHV2/HSV2 (genital herpes virus)

HHV6 (Types A & B) (human herpes virus 6)

HPV (16/18) (human papillomavirus)

HPV (6/11) (human papillomavirus)

HTLV1 (Human T-cell lymphotropic Virus)
HBV (Hepatitis B Virus)
HCV (Hepatitis C Virus)

HIV (Human Immunodeficiency Virus)

SOT terminates its gene replication sequences, thus eliminating the next lifecycle and eradicating it from the body. If a patient has multiple active infections, then multiple SOT treatments will be needed for each infection. 

SOT is not an immune treatment, because it does not work by modulating the immune system. Because it is highly compatible with the patient, the side effects are usually minimal. Potential side effects may include headaches, body aches, general malaise, sweating, diarrhea, cough, fever, (generally <=101°F), and mild to moderate flulike symptoms. Usually, these symptoms resolve within 24-48 hours or a week at most.

SOT for Cancer: SOT induces rapid apoptosis in circulating tumor cells (CTCs), circulating cancer stem cells (CSCs), primary tumor cells, and metastatic tumors. In addition, it is able to cross the blood-brain barrier. As it penetrates into these cells it will interfere with their ability to replicate. The doctor  will  recommend a PET/CT, CT, or MRI scan prior to the SOT to assess the patient’s cancer for any metastasis. To reduce the risk of mild to severe adverse reactions, and to adjust the SOT dosing and timing, according to each individual case. Cancer with metastasis could result in Tumor Lysis Syndrome (TLS), which can be life threatening.